North America Glucagon like Peptide - 1 Agonists Market 2019-2024 by Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide) & Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

By In The News
March 21, 2019 in The Headlines

Recommended Posts

In The News

Posted March 21, 2019

- Share

Posted March 21, 2019

DUBLIN, March 21, 2019 /PRNewswire/ -- The "North America Glucagon like Peptide - 1 (GLP - 1) Agonists Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. GLP-1 agonist market holds 17.2% of the total North American diabetes...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219854
2. Jaydee
  16745
3. Kip Powick
  12211
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.1k
- Total Posts
  
  558.6k

Sign In

North America Glucagon like Peptide - 1 Agonists Market 2019-2024 by Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide) & Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support